Innovation
New: Priority Review Vouchers and Innovation
17 February 2011
This OHE Seminar Briefing recounts a presentation by Prof Henry Grabowski on US Priority Review Vouchers, intended to provide an incentive for the development of drugs…
Update: Value-Based Pricing in the UK
11 January 2011
Value-based pricing for new medicines, proposed as part of UK health care reform, would create a QALY-plus approach for drugs approved starting 1 January 2014. For…
New Drugs to Tackle Antimicrobial Resistance: Analysis of EU Policy Options
1 April 2011
Antimicrobial resistance (AMR) to drugs is a natural and unavoidable consequence of treating infectious diseases. A growing global public health threat, AMR reduces the chances of…
Pharmaceutical Pricing in Europe: Is Differential Pricing a Win-Win Solution?
1 February 2011
This paper examines the potentially positive impact of differential pricing in Europe and the overall negative effects of international reference pricing (IRP) measures. The authors point…
Priority Review Vouchers to Encourage Innovation for Neglected Diseases
1 January 2011
Priority Review Vouchers (PRVs) are awarded in the US to companies that gain approval there for a new drug for one of sixteen tropical diseases, under…
Seminar Briefing on Science Policy
23 December 2010
At a recent OHE seminar, Prof Ben Martin (Science and Technology Policy Studies at SPRU, University of Sussex) presented the results of his extensive literature review…
Report on Orphan Drugs Released
9 December 2010
OHE Consulting has released new research on orphan medicinal products (OMPs) in Europe that assesses the effects of the European Union’s 1999 Regulation on Orphan Medicinal…
Access to Orphan Drugs in the EU
21 October 2010
Legislation in the EU provides incentives for the developmeng of drugs for rare diseases, known as orphan medicinal products (OMPs). At a recent conference, OHE’s Dr…
Biomedical and Health Research Spillovers in the UK
14 October 2010
Research spillovers exist when research by one organisation creates increased output for other organisations that operate in the same or other sector of the economy. Given…